Interestingly, taking into account the mechanisms by which mechanistic target of rapamycin (mTOR) influences insulin resistance by acting on Foxo1 and lipin1; regulating lipid metabolism via SREBPs; interfering with the intestinal microbiota via TLRs; moderating oxidative stress through PIG3, p53, and JNK; and counteracting autophagy, inflammation, genetic polymorphisms, and epigenetics in NAFLD, the authors have stressed the importance of mTOR as an influencing factor of NAFLD [170]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.